# US 10,765,644 B2 · Methods for the treatment of hepatitis C

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,644 B2
- Document ID: US10765644B2
- Status: Granted
- Kind: B2
- Application number: 16/100,481
- Filed: 2018-08-10
- Published: 2018-12-06
- Granted: 2020-09-08
- Earliest claimed: 2015-12-08
- Assignees: Cipla Limited
- Applicants: Cipla Limited
- Inventors: Geena Malhotra; Kalpana Joshi
- Web page: https://patentgrep.com/patent/US10765644B2

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.

## Claims

### Claim 1

A pharmaceutical composition comprising hexestrol, or a pharmaceutically acceptable salt or ester thereof, in an amount effective to treat hepatitis C and sofosbuvir.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition comprises hexestrol.

### Claim 3

A kit comprising hexestrol, or a pharmaceutically acceptable salt or ester thereof, in an amount effective to treat hepatitis C and sofosbuvir.

### Claim 4 (depends on 3)

The kit according to claim 3, wherein the kit comprises hexestrol.

### Claim 5 (depends on 3)

The kit according to claim 3, wherein the hexestrol, or pharmaceutically acceptable salt or ester thereof, is in a separate dosage form from the sofosbuvir.